The effect of dietary phytosphingosine on cholesterol levels and insulin sensitivity in subjects with the metabolic syndrome

European Journal of Clinical Nutrition

Volumn 64, Issue 4, 2010, Pages 419-423

  Snel, M ^a   Sleddering, M A ^a   Pijl, H ^a   Nieuwenhuizen, W F ^b   Frolich M ^a   Havekes, L M ^a,b   Romijn, J A ^a   Jazet, I M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

Author keywords

Cholesterol; Insulin resistance; Intravenous glucose tolerance test; Metabolic syndrome; Sphingolipids

Indexed keywords

CHOLESTEROL; COSMOFERM; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHYTOSPHINGOSINE; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; FAT INTAKE; GLUCOSE BLOOD LEVEL; SPHINGOLIPID; SPHINGOSINE;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; BODY FAT; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FATTY ACID METABOLISM; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEARTBURN; HORMONE DETERMINATION; HUMAN; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MALE; METABOLIC SYNDROME X; NAUSEA; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; ADMINISTRATION AND DOSAGE; BLOOD; FAT INTAKE; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED;

BLOOD GLUCOSE; CHOLESTEROL; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DIETARY FATS; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; SPHINGOLIPIDS; SPHINGOSINE; TRIGLYCERIDES;

RODENTIA;

EID: 77950628612     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/ejcn.2009.154     Document Type: Article

References (23)

1. Alberti KG, Zimmet P, Shaw J (2006). Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 23, 469-480.
2. Barrenetxe J, Aranguren P, Grijalba A, Martinez-Penuela JM, Marzo F, Urdaneta E (2006). Effect of dietary quercetin and sphingomyelin on intestinal nutrient absorption and animal growth. Br J Nutr 95, 455-461.
3. Berra B, Colombo I, Sottocornola E, Giacosa A (2002). Dietary sphingolipids in colorectal cancer prevention. Eur J Cancer Prev 11, 193-197. (Pubitemid 34478438)
4. Duivenvoorden I, Voshol PJ, Rensen PC, van Duyvenvoorde W, Romijn JA, Emeis JJ et al. (2006). Dietary sphingolipids lower plasma cholesterol and triacylglycerol and prevent liver steatosis in APOE*3Leiden mice. Am J Clin Nutr 84, 312-321. (Pubitemid 44699139)
5. Ford ES (2005). Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28, 1769-1778.
6. Ford ES, Giles WH, Dietz WH (2002). Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287, 356-359. (Pubitemid 34251969)
7. Harder T, Simons K (1997). Caveolae, DIGs, and the dynamics of sphingolipid-cholesterol microdomains. Curr Opin Cell Biol 9, 534-542. (Pubitemid 27354763)
8. Hendriks HF, Brink EJ, Meijer GW, Princen HM, Ntanios FY (2003). Safety of long-term consumption of plant sterol esters-enriched spread. Eur J Clin Nutr 57, 681-692.
9. Hendriks HF, Weststrate JA, van Vliet T, Meijer GW (1999). Spreads enriched with three different levels of vegetable oil sterols and the degree of cholesterol lowering in normocholesterolaemic and mildly hypercholesterolaemic subjects. Eur J Clin Nutr 53, 319-327. (Pubitemid 29164264)
10. Imaizumi K, Tominaga A, Sato M, Sugano M (1992). Effects of dietary sphingolipids on levels of serum and liver lipids in rats. Nutr Res 12, 543-548.
11. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M et al. (2001). Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24, 683-689. (Pubitemid 32893993)
12. Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C et al. (2004). Acarbose attenuates experimental non-alcoholic steatohepatitis. Biochem Biophys Res Commun 315, 699-703.
13. Lundback K (1962). Intravenous glucose tolerance as a tool in definition and diagnosis of diabetes mellitus. Br Med J 1, 1507-1513.
14. Merrill Jr AH, Schmelz EM, Dillehay DL, Spiegel S, Shayman JA, Schroeder JJ et al. (1997). Sphingolipids-the enigmatic lipid class: biochemistry, physiology, and pathophysiology. Toxicol Appl Pharmacol 142, 208-225.
15. Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E (1995). Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med 333, 1308-1312.
16. Noh SK, Koo SI (2004). Milk sphingomyelin is more effective than egg sphingomyelin in inhibiting intestinal absorption of cholesterol and fat in rats. J Nutr 134, 2611-2616.
17. Okada K, Yanagawa T, Warabi E, Yamastu K, Uwayama J, Takeda K et al. (2009). The alpha-glucosidase inhibitor acarbose prevents obesity and simple steatosis in sequestosome 1/A170/p62 deficient mice. Hepatol Res 39, 490-500.
18. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI (2005). Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54, 603-608.
19. Ravikumar B, Gerrard J, Dalla MC, Firbank MJ, Lane A, English PT et al. (2008). Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content. Diabetes 57, 2288-2295.
20. Schmelz EM, Crall KJ, Larocque R, Dillehay DL, Merrill Jr AH (1994). Uptake and metabolism of sphingolipids in isolated intestinal loops of mice. J Nutr 124, 702-712.
21. Segal P, Eliahou HE, Petzinna D, Neuser D, Bruckner A, Spengler M (2005). Long-term efficacy and tolerability of acarbose treatment in patients with type 2 diabetes mellitus. Clin Drug Investig 25, 589-595. (Pubitemid 41379849)
22. Tang JL, Armitage JM, Lancaster T, Silagy CA, Fowler GH, Neil HA (1998). Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. BMJ 316, 1213-1220.
23. Vesper H, Schmelz EM, Nikolova-Karakashian MN, Dillehay DL, Lynch DV, Merrill Jr AH (1999). Sphingolipids in food and the emerging importance of sphingolipids to nutrition. J Nutr 129, 1239-1250.